TY - JOUR
T1 - Mesenchymal stem cells in primary Sjögren’s syndrome
T2 - Prospective and challenges
AU - Chen, Weiqian
AU - Yu, Ye
AU - Ma, Jilin
AU - Olsen, Nancy
AU - Lin, Jin
N1 - Funding Information:
This study is supported in part by the grants from National Natural Science Foundation of China (81701600 and 81274161) and Natural Science Foundation of Zhejiang Province (LQ17H100001, LGF18H100001, and LY17H100006).
Publisher Copyright:
Copyright © 2018 Weiqian Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
PY - 2018
Y1 - 2018
N2 - Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.
AB - Primary Sjögren’s syndrome (pSS) is a chronic systemic inflammatory autoimmune disease characterized by lymphocytic infiltrates in exocrine glands. Current approaches do not control harmful autoimmune attacks or prevent irreversible damage and have considerable side effects. Mesenchymal stem cells (MSCs) have been effective in the treatment of several autoimmune diseases. The objective of this review is to illustrate the potential therapeutic role of MSCs in pSS. We summarize the recent advances in what is known about their immunomodulatory function and therapeutic applications in pSS. MSC transfusion can suppress autoimmunity and restore salivary gland secretory function in mouse models and patients with pSS by inducing regulatory T cells, suppressing Th1, Th17, and T follicular helper cell responses. In addition, MSCs can differentiate into salivary epithelial cells, presenting an option as a suitable alternative treatment. We also discuss current bioengineering methods which improve functions of MSCs for pSS. However, there remain many challenges to overcome before their wide clinical application.
UR - http://www.scopus.com/inward/record.url?scp=85062892147&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062892147&partnerID=8YFLogxK
U2 - 10.1155/2018/4357865
DO - 10.1155/2018/4357865
M3 - Review article
C2 - 30305818
AN - SCOPUS:85062892147
VL - 2018
JO - Stem Cells International
JF - Stem Cells International
SN - 1687-9678
M1 - 4357865
ER -